Hanmi Pharm. Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 128940.KS | 009420.KS | 000105.KS | 0QFP.IL | 000640.KS | 195940.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 5.90T | 2.01T | 4.95T | 4.46T | 600.98B | 1.04T |
| P/E (TTM) | — | — | — | 18.8 | — | — |
| Forward P/E | — | — | — | — | — | — |
| Price/book | — | — | — | 2.1 | — | — |
| Dividend yield | 0.47% | — | 0.92% | 7.74% | 1.93% | 1.20% |
| 1-year change | −7.73% | −16.33% | −35.70% | 0.00% | −15.76% | −30.39% |
| Today | +9.80% | +6.19% | +1.66% | +156.25% | +1.48% | +7.01% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 128940.KS news ›GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin
Business GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin Published : Oct. 30, 2026 - 12:49:01 GC Biopharma and Hanmi Pharmaceutical announced on Friday that they have signed an exclusive licensing-out agreement…
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Oct 29, 2026, 08:45 ET BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional payments upon certain development and commercial milestones, and tiered royalties on net sales of…
Hanmi Pharm Q3 net income down 69.1% to $10.6 mil.
Hanmi Pharm on Tuesday reported a third-quarter net income of 14 billion won ($10.6 million), down 69.1 percent from a year earlier. The Korean pharmaceutical company said in a regulatory filing that operating profit for the July-September…
Hanmi Pharm prices domestic obesity drug Epe at half the cost of Mounjaro
First month at 129,800 won, maintenance dose at 299,200 won Early-entry and long-term cost relief backed by Pyeongtaek plant supply chain Aggressive pricing set to reshape market dominated by foreign brands South Korea's first homegrown…
Hanmi Pharm's obesity treatment Eppe wins domestic approval
Hanmi Pharm headquarters in Songpa, Seoul / Courtesy of Hanmi Pharm Eppe is the 45th novel drug developed in Korea and the country's first domestically developed GLP-1-based obesity drug. It has been approved in five doses: 2, 4, 6, 8 and…
Hanmi Pharm unveils FAP-targeting SMDC to overcome ADC limitations at US conference
Small-molecule drug conjugate presented at Discovery on Target 2026 in Boston Next-generation anticancer modality also set for oral presentation at Nature Conference Hanmi Pharm has made its global debut with a next-generation anticancer…
Hanmi Pharm Revives Returned Drug Candidates... Open Innovation in the Spotlight
asiae.co.kr Published 06 Oct.2026 08:21(KST) Efe, Efinopegdutide, Belvarafenib, and Poseltinib A noteworthy case has emerged in which Hanmi Pharm revitalized a new drug candidate, the rights to which it had regained,
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- koreatimes.co.kr2
- mbiz.heraldcorp.com2
- asiae.co.kr1
- koreaherald.com1
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.